![mRNA Cancer Vaccines: The Personalised Revolution](https://cdn.slatesource.com/3/1/0/310b9df3-900b-461a-b072-b5fc31178866.webp) # mRNA Cancer Vaccines: The Personalised Revolution - [Made in Slatesource](https://slatesource.com/@steph/mrna-cancer-vaccines-the-personalised-revolution) - By [Steph](https://slatesource.com/@steph) - Created on Jul 17, 2026 > Nearly 90% of the patients whose immune systems responded to the vaccine are still alive six years later. For pancreatic cancer, that is not a result we ever expected to see. ## A NewNew KindKind of VaccineVaccine TraditionalTraditional vaccinesvaccines teachteach your immuneimmune systemsystem to recogniserecognise a specificspecific, sharedshared targettarget, such as a viralviral proteinprotein. mRNAmRNA cancercancer vaccinesvaccines do somethingsomething fundamentallyfundamentally differentdifferent: they are builtbuilt from a biopsybiopsy of your ownown tumourtumour. ScientistsScientists sequencesequence the DNADNA, identifyidentify the mutationsmutations uniqueunique to your cancercancer, and encodeencode up to 34 of those targetstargets into a customcustom mRNAmRNA strandstrand. InjectedInjected into your armarm, it trainstrains your immuneimmune cellscells to hunthunt downdown cellscells carryingcarrying those exactexact mutationsmutations. No twotwo patientspatients receivereceive the samesame vaccinevaccine. The technologytechnology was alwaysalways theoreticallytheoretically possiblepossible but practicallypractically out of reachreach. The COVID-19COVID-19 pandemicpandemic changedchanged that. ModernaModerna and BioNTechBioNTech, forcedforced to manufacturemanufacture billionsbillions of mRNAmRNA dosesdoses at speedspeed, builtbuilt the industrialindustrial infrastructureinfrastructure that nownow makesmakes personalisedpersonalised cancercancer vaccinesvaccines manufacturablemanufacturable in roughlyroughly sixsix weeksweeks perper patientpatient. The samesame lipidlipid nanoparticlenanoparticle deliverydelivery systemsystem that carriedcarried COVIDCOVID spikespike proteinprotein into cellscells nownow carriescarries tumour-specifictumour-specific neoantigensneoantigens to the immuneimmune systemsystem. subtitle: The 2026 cancer pipeline: where each stands 0% \[icon:CHECK\] Melanoma (Moderna / mRNA-4157 + Keytruda): Phase 3 INTerpath-001 ongoing. Phase 2b showed 49% lower risk of recurrence or death and 62% lower risk of distant metastasis vs Keytruda alone. Regulatory submission from Moderna expected in 2026. \[icon:CHECK\] Pancreatic cancer (BioNTech / BNT122 + Keytruda): Phase 2 IMCODE003 ongoing. Phase 1 six-year follow-up (AACR 2026): of 8 immune responders, 6 remain alive. Five-year pancreatic survival rate is normally around 13%. \[icon:CHECK\] Non-small-cell lung cancer (Moderna / mRNA-4157 + Keytruda): Phase 3 INTerpath-002 underway in resected NSCLC (stages IB to IIIA). First readout expected late 2026 to 2027. \[icon:CHECK\] Colorectal cancer (multiple): KRAS-targeted mRNA vaccines in Phase 2. KRAS mutations drive roughly 40% of colorectal cancers and have resisted targeted therapy for 40 years. \[icon:CHECK\] Glioblastoma (brain tumour): first-in-human mRNA vaccine trial completed. An mRNA approach that reprogrammed the immune system to treat this aggressive brain tumour showed measurable response in the early human cohort, published July 2026. \[icon:CHECK\] Breast, bladder, kidney, head and neck cancers: early Phase 1 or Phase 2 trials active across Moderna, BioNTech, Gritstone Bio, and several academic centres. \[icon:CLOCK\] Regulatory milestone watch: if INTerpath-001 (melanoma) reads out positive, it would be the first Phase 3 approval of any personalised cancer vaccine in history. Reduction in melanoma recurrence or death (Phase 2b) 49% lower vs immunotherapy alone Pancreatic cancer responders alive at 6 years (Phase 1) approximately 90% Active clinical trials using mRNA cancer vaccines (2026) more than 120 worldwide Tumour mutations encoded per personalised vaccine up to 34 neoantigens per patient Time to manufacture a personalised vaccine from biopsy approximately 6 weeks Forecast peak sales for mRNA-4157 V940 (GlobalData, 2031) $2.3 billion annually Normal 5-year survival for pancreatic cancer approximately 13% How the manufacturing works. After surgical removal of a tumour, a sample is sent to Moderna or BioNTech's facility. The tumour's DNA is fully sequenced, then compared against the patient's healthy DNA to identify somatic mutations that exist only in the cancer cells. A proprietary algorithm ranks those mutations by immunogenicity: how likely each is to trigger a T-cell response. The top candidates, up to 34, are encoded into an mRNA sequence, synthesised, encapsulated in lipid nanoparticles, an # Is personalised cancer vaccination the future of oncology, or is the hype ahead of the data? The Phase 2b melanoma data and the six-year pancreatic survival figures are remarkable. But Phase 3 results have not yet read out, the approach costs hundreds of thousands of dollars per patient, and six weeks of manufacturing time is not viable for fast-growing tumours. Is this a genuine revolution in cancer treatment, or a targeted benefit for a narrow group of patients who can access it? No comments yet. Be the first. Log in to comment What happens next. Moderna expects to submit mRNA-4157 (V940) for regulatory approval in melanoma in 2026, with FDA review expected to take 12 months. A positive verdict in melanoma would likely accelerate approvals across lung, colorectal, and other tumour types. BioNTech has said it expects to publish Phase 2 pancreatic data in 2026 to 2027. The first approval, if it comes, will unlock reimbursement negotiations in the US, EU, UK, and Japan simultaneously, setting the price that determines whe [Memorial Sloan Kettering: pancreatic cancer mRNA vaccine, Phase 1 six-year results (AACR 2026)](https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out?utm_source=slatesource) [Moderna mRNA-4157 plus Keytruda: Phase 2b melanoma results and Phase 3 programme overview](https://www.clinicaltrialsarena.com/news/moderna-cancer-vaccine-intismeran-autogene-keytruda-melanoma-phase-iib/?utm_source=slatesource) [Cancer Research Institute: 2026 Cancer Immunotherapy Insights and Impact Report](https://www.cancerresearch.org/cancer-immunotherapy-report-2026?utm_source=slatesource)